AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10823594 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 44
Study 8894937 — intervention group
Group type: EXPERIMENTAL
Intervention: d-sotalol (2 mg/kg IV in 15 min, followed by 1 mg/kg per hour)
Number of subjects: 15
Study 2003079 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect blood pressure methods (bell and diaphragm components of the stethoscope)
Number of subjects: 30
Study 2003079 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct arterial method (radial intraarterial cannula)
Number of subjects: 30
Study 2003079 — intervention group
Group type: EXPERIMENTAL
Intervention: Random-zero (RZ) sphygmomanometer for indirect blood pressure
Number of subjects: 30
Study 6152120 — intervention group
Group type: EXPERIMENTAL
Intervention: Fansidar (1 tablet a week)
Number of subjects: 173
Study 6152120 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine (300 mg weekly)
Number of subjects: 173
Study 29059120 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily Engagement in Meaningful Activity (DEMA)
Number of subjects: 40
Study 29059120 — intervention group
Group type: COMPARATOR
Intervention: Information Support (Control)
Number of subjects: 40
Study 25461390 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental vitamin D (cholecalciferol) 4000 IU
Number of subjects: 46
Study 25461390 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental vitamin D (cholecalciferol) 8000 IU
Number of subjects: 46
Study 25461390 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 25461390 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental vitamin D (4000 IU and 8000 IU) in vitamin D insufficient subjects (serum 25(OH)D<29 ng/mL)
Number of subjects: 46
Study 22971719 — intervention group
Group type: COMPARATOR
Intervention: Two types of antiplatelet agents (Group I)
Number of subjects: 447
Study 22971719 — intervention group
Group type: EXPERIMENTAL
Intervention: Single antiplatelet agent plus warfarin (Group II)
Number of subjects: 447
Study 22971719 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin therapy
Number of subjects: 447
Study 22971719 — intervention group
Group type: COMPARATOR
Intervention: CHADS2 score comparison
Number of subjects: 447
Study 21480316 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term low-dose peginterferon therapy
Number of subjects: 1050
Study 21480316 — intervention group
Group type: COMPARATOR
Intervention: Control group (no peginterferon therapy)
Number of subjects: 1050
Study 19657203 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic touch (contact on neck and shoulders, delivered twice daily for 3 days)
Number of subjects: 65
Study 19657203 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (mimic treatment identical in appearance)
Number of subjects: 65
Study 19657203 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 65
Study 16445337 — intervention group
Group type: EXPERIMENTAL
Intervention: Shortwave diathermy (SW)
Number of subjects: 30
Study 16445337 — intervention group
Group type: EXPERIMENTAL
Intervention: SW and nonsteroidal anti-inflammatory drugs
Number of subjects: 30
Study 16445337 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 30
Study 15789920 — intervention group
Group type: COMPARATOR
Intervention: Antithyroid drugs
Number of subjects: 64
Study 15789920 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithyroid drugs + Azathioprine
Number of subjects: 64
Study 11331684 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingent TV (pedaling a stationary cycle ergometer)
Number of subjects: 10
Study 11331684 — intervention group
Group type: COMPARATOR
Intervention: Control (no contingent TV)
Number of subjects: 10
Study 9250136 — intervention group
Group type: EXPERIMENTAL
Intervention: Anorexia nervosa patients (AN1 to AN6 phases)
Number of subjects: 15
Study 9250136 — intervention group
Group type: EXPERIMENTAL
Intervention: Anorexia nervosa patients (AN1 and AN2 phases)
Number of subjects: 15
Study 9250136 — intervention group
Group type: EXPERIMENTAL
Intervention: Anorexia nervosa patients (AN3 and AN4 phases)
Number of subjects: 15
Study 9250136 — intervention group
Group type: EXPERIMENTAL
Intervention: Anorexia nervosa patients (AN5 and AN6 phases)
Number of subjects: 15
Study 9250136 — intervention group
Group type: EXPERIMENTAL
Intervention: Anorexia nervosa patients (all phases)
Number of subjects: 15
Study 9250136 — intervention group
Group type: EXPERIMENTAL
Intervention: Anorexia nervosa patients (AN4, AN5, and AN6 phases)
Number of subjects: 15
Study 9250136 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 15
Study 7506400 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon laser photocoagulation treatment
Number of subjects: 271
Study 7506400 — intervention group
Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 271
Study 30122772 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating rapid palatal expansion and constriction (RPE/C)
Number of subjects: 36
Study 30122772 — intervention group
Group type: COMPARATOR
Intervention: Rapid palatal expansion (RPE)
Number of subjects: 36
Study 30122772 — intervention group
Group type: EXPERIMENTAL
Intervention: RPE/C
Number of subjects: 36
Study 28818095 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegloticase every 2 weeks (Q2w)
Number of subjects: 1695
Study 28818095 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegloticase every 4 weeks (Q4w)
Number of subjects: 1695
Study 28818095 — intervention group
Group type: COMPARATOR
Intervention: NIAID/FAAN criteria for anaphylaxis
Number of subjects: 1695
Study 26630989 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate aerobic exercise (at least 30 min for five times per week)
Number of subjects: 120
Study 26630989 — intervention group
Group type: COMPARATOR
Intervention: Controlled group (exercise not mandatorily required)
Number of subjects: 120
Study 23884073 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation (PE) sessions
Number of subjects: 198
Study 23884073 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (pegylated interferon alfa‐2a and ribavirin therapy) without psychoeducation
Number of subjects: 198
Study 22030226 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-calorie diet (LCD)
Number of subjects: 40
Study 18427001 — intervention group
Group type: EXPERIMENTAL
Intervention: p53 expression
Number of subjects: 45
Study 18427001 — intervention group
Group type: EXPERIMENTAL
Intervention: Bcl-xL expression
Number of subjects: 45
Study 18427001 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk groups based on p53 and Bcl-xL expression
Number of subjects: 45
Study 16540603 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline
Number of subjects: 157
Study 16540603 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157
Study 12859445 — intervention group
Group type: EXPERIMENTAL
Intervention: UGRP1‐112G/A polymorphism
Number of subjects: 131
Study 12859445 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of at least one A allele in genotype
Number of subjects: 131
Study 12859445 — intervention group
Group type: EXPERIMENTAL
Intervention: ‐112A allele prevalence
Number of subjects: 131
Study 12505968 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeved bronchoscope
Number of subjects: 50
Study 12505968 — intervention group
Group type: COMPARATOR
Intervention: Nonsleeved bronchoscope
Number of subjects: 50
Study 10791186 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg i.v.
Number of subjects: 20
Study 10791186 — intervention group
Group type: COMPARATOR
Intervention: Saline 2 cc i.v. (Control)
Number of subjects: 20
Study 9715298 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal pethidine 5% (50 mg/ml) 0.5 mg/kg
Number of subjects: 100
Study 9715298 — intervention group
Group type: COMPARATOR
Intervention: 5% lignocaine 1 ml
Number of subjects: 100
Study 1864086 — intervention group
Group type: COMPARATOR
Intervention: Topical prednisolone eye drops (tapering dosage)
Number of subjects: 0
Study 1864086 — intervention group
Group type: COMPARATOR
Intervention: Oral acyclovir
Number of subjects: 0
Study 1864086 — intervention group
Group type: COMPARATOR
Intervention: Placebo eye drops
Number of subjects: 0
Study 1864086 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 0
Study 6824996 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 (PGE2) at doses of 0.1 mg, 0.5 mg, and 1.0 mg
Number of subjects: 6
Study 6824996 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA)
Number of subjects: 6
Study 6824996 — intervention group
Group type: COMPARATOR
Intervention: Control (140 mM hydrochloric acid)
Number of subjects: 6
Study 30229406 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonfluoroscopic catheter visualization (NFCV)
Number of subjects: 80
Study 30229406 — intervention group
Group type: COMPARATOR
Intervention: Established mapping systems and fluoroscopy as needed (CONV group)
Number of subjects: 80
Study 30229406 — intervention group
Group type: EXPERIMENTAL
Intervention: NFCV
Number of subjects: 80
Study 29540181 — intervention group
Group type: EXPERIMENTAL
Intervention: Social media intervention group (SM)
Number of subjects: 37
Study 29540181 — intervention group
Group type: COMPARATOR
Intervention: Control group (no social media intervention)
Number of subjects: 37
Study 26787469 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile health supported physical activity intervention
Number of subjects: 68
Study 26787469 — intervention group
Group type: COMPARATOR
Intervention: Standard care (physical activity advice booklet only)
Number of subjects: 68
Study 24588936 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegloticase
Number of subjects: 169
Study 22334085 — intervention group
Group type: EXPERIMENTAL
Intervention: Oily emulsion of DHA-phospholipids containing melatonin and tryptophan
Number of subjects: 25
Study 22334085 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 20497747 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone ER
Number of subjects: 0
Study 17945530 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren (300 mg qd)
Number of subjects: 27
Study 17945530 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril (10 mg qd)
Number of subjects: 27
Study 17945530 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 16230121 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous low-dose heparin (3 x 5000 IU/day for 2 days, then 2 x 5000 IU/day for 12 days, maintenance 5000 IU/day)
Number of subjects: 41
Study 16230121 — intervention group
Group type: COMPARATOR
Intervention: Oral pentosan polysulfate (PPS) alone
Number of subjects: 41
Study 16230121 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous low-dose heparin and oral PPS
Number of subjects: 41
Study 11850096 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin treatment for 4 weeks
Number of subjects: 30
Study 11850096 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin treatment for 12 weeks
Number of subjects: 30
Study 11850096 — intervention group
Group type: COMPARATOR
Intervention: Oral agents (comparison group)
Number of subjects: 30
Study 9859881 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive smooth speech
Number of subjects: 0
Study 9859881 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-home smooth speech
Number of subjects: 0
Study 9859881 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive electromyography feedback
Number of subjects: 0
Study 9859881 — intervention group
Group type: COMPARATOR
Intervention: Nontreatment
Number of subjects: 0
Study 7625338 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fat diet (LF) - 20% of energy as fat, 67% as carbohydrate, 13% as protein; 4.80 kJ/g
Number of subjects: 6
Study 7625338 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium fat diet (MF) - 40% of energy as fat, 47% as carbohydrate, 13% as protein; 5.59 kJ/g
Number of subjects: 6
Study 7625338 — intervention group
Group type: EXPERIMENTAL
Intervention: High fat diet (HF) - 60% of energy as fat, 27% as carbohydrate, 13% as protein; 7.04 kJ/g
Number of subjects: 6
Study 7625338 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate balance
Number of subjects: 6
Study 7625338 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat balance
Number of subjects: 6
Study 2199131 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg (+/‐)‐nicardipine
Number of subjects: 79
Study 2199131 — intervention group
Group type: COMPARATOR
Intervention: 10 mg nifedipine
Number of subjects: 79
Study 150813 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulfate monohydrate, 411 mg total daily dosage
Number of subjects: 22
Study 150813 — intervention group
Group type: COMPARATOR
Intervention: Lactose placebo
Number of subjects: 22
Study 29242413 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily assisted physical exercise (one session daily starting from one week of postnatal age, including range-of-motion exercises with gentle compression, flexion and extension of all extremities for 10-15 min)
Number of subjects: 50
Study 29242413 — intervention group
Group type: COMPARATOR
Intervention: Routine care (Control group, no massage or exercise)
Number of subjects: 50
Study 28256333 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight Control (GI)
Number of subjects: 40
Study 26125277 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (n=47)
Number of subjects: 107
Study 26125277 — intervention group
Group type: COMPARATOR
Intervention: Sertraline (n=60)
Number of subjects: 107
Study 26125277 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 107
Study 26125277 — intervention group
Group type: COMPARATOR
Intervention: Sertraline
Number of subjects: 107
Study 26125277 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 107
Study 23102845 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg FSH im once a day for 4 days (N = 5)
Number of subjects: 13
Study 23102845 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg FSH sc on Day 3 and Day 5 (N = 4)
Number of subjects: 13
Study 23102845 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg FSH plus 2.5 mg LH sc on Day 3 and Day 5 (N = 4)
Number of subjects: 13
Study 22003109 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized acuity mean measurement (CAMM6)
Number of subjects: 100
Study 22003109 — intervention group
Group type: COMPARATOR
Intervention: ETDRS chart
Number of subjects: 100
Study 22003109 — intervention group
Group type: COMPARATOR
Intervention: ETDRS measurements
Number of subjects: 100
Study 22003109 — intervention group
Group type: EXPERIMENTAL
Intervention: CAMM6 measurements
Number of subjects: 100
Study 22003109 — intervention group
Group type: EXPERIMENTAL
Intervention: CAMM6
Number of subjects: 100
Study 18433659 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical restraints applied during the first 2 hours of admission
Number of subjects: 301
Study 18433659 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 301
Study 18433659 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense agitation
Number of subjects: 301
Study 18433659 — intervention group
Group type: EXPERIMENTAL
Intervention: Extreme agitation
Number of subjects: 301
Study 18433659 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance misuse
Number of subjects: 301
Study 18433659 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnoses other than psychosis
Number of subjects: 301
Study 18433659 — intervention group
Group type: EXPERIMENTAL
Intervention: Time of admission in the morning
Number of subjects: 301
Study 16501860 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose gemcitabine infusion (250 mg/m2)
Number of subjects: 25
Study 16501860 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose gemcitabine infusion (1000 mg/m2)
Number of subjects: 25
Study 12928902 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir 200 mg five times/day for 3 weeks (Group A)
Number of subjects: 30
Study 12928902 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir 200 mg five times/day for 1 year (Group B)
Number of subjects: 30
Study 12928902 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir 200 mg five times/day in combination with MMF 1 g twice daily for 1 year (Group C)
Number of subjects: 30
Study 11164664 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) 0.1 mg/kg injected subcutaneously three times a week
Number of subjects: 20
Study 11164664 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline solution injected at the same times as GH
Number of subjects: 20
Study 9217519 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (2 mg)
Number of subjects: 98
Study 9217519 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (5 mg)
Number of subjects: 98
Study 9217519 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of lorazepam and haloperidol
Number of subjects: 98
Study 7951573 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroglobulin (Tg) concentration in cyst fluid
Number of subjects: 125
Study 7951573 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactic dehydrogenase (LDH) isozyme patterns in cyst fluid
Number of subjects: 125
Study 2823840 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 aPTT‐U low molecular weight heparin plus 0.5 mg dihydroergotamine (HNMD; Embolex NM)
Number of subjects: 160
Study 2823840 — intervention group
Group type: COMPARATOR
Intervention: 5000 IU of the heparin‐dihydroergotamine combination Heparin‐Dihydergot (twice daily)
Number of subjects: 160
Study 2278166 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (n = 17)
Number of subjects: 33
Study 2278166 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (n = 16)
Number of subjects: 33
Study 49984 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (Hydroxyurea) only
Number of subjects: 234
Study 49984 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy only
Number of subjects: 234
Study 49984 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy and radiotherapy
Number of subjects: 234
Study 49984 — intervention group
Group type: COMPARATOR
Intervention: Observation only
Number of subjects: 234
Study 31811737 — intervention group
Group type: EXPERIMENTAL
Intervention: WeChat-based 'Three Good Things' intervention
Number of subjects: 73
Study 31811737 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 73
Study 30983166 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40mg daily
Number of subjects: 3002
Study 28902426 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical therapy aiming at pocket elimination with systemic antibiotics
Number of subjects: 100
Study 28902426 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical therapy aiming at pocket elimination with antiseptic agent for implant surface decontamination
Number of subjects: 100
Study 28902426 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical therapy aiming at pocket elimination with both systemic antibiotics and antiseptic agent
Number of subjects: 100
Study 28902426 — intervention group
Group type: COMPARATOR
Intervention: Surgical therapy aiming at pocket elimination (control group)
Number of subjects: 100
Study 26323937 — intervention group
Group type: EXPERIMENTAL
Intervention: Benznidazole
Number of subjects: 2854
Study 26323937 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2854
Study 23541376 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure <140 mm Hg
Number of subjects: 10705
Study 23541376 — intervention group
Group type: COMPARATOR
Intervention: Systolic blood pressure ≥140 mm Hg
Number of subjects: 10705
Study 23541376 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure <120 mm Hg
Number of subjects: 10705
Study 21366634 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori eradication therapy (ranitidine bismuth citrate 400 mg and clarithromycin 500 mg twice daily for 2 weeks)
Number of subjects: 1558
Study 21366634 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1558
Study 21366634 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori eradication therapy
Number of subjects: 1558
Study 18853180 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid replacement at 66% (HI)
Number of subjects: 6
Study 18853180 — intervention group
Group type: COMPARATOR
Intervention: Fluid replacement at 0% (LO)
Number of subjects: 6
Study 18853180 — intervention group
Group type: COMPARATOR
Intervention: Fluid replacement at 33% (LO)
Number of subjects: 6
Study 18853180 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid replacement at 100% (HI)
Number of subjects: 6
Study 17448975 — intervention group
Group type: EXPERIMENTAL
Intervention: Reversed saphenous vein
Number of subjects: 85
Study 17448975 — intervention group
Group type: COMPARATOR
Intervention: Collagen impregnated woven polyester prosthesis
Number of subjects: 85
Study 12970274 — intervention group
Group type: EXPERIMENTAL
Intervention: GH at 25.0 microg/kg x day (pediatric dose)
Number of subjects: 149
Study 12970274 — intervention group
Group type: EXPERIMENTAL
Intervention: GH at 12.5 microg/kg x day (adult dose)
Number of subjects: 149
Study 12970274 — intervention group
Group type: COMPARATOR
Intervention: No GH treatment (control)
Number of subjects: 149
Study 10784079 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent training only
Number of subjects: 158
Study 10784079 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-day treatment classroom only
Number of subjects: 158
Study 10784079 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of parent training with classroom treatment
Number of subjects: 158
Study 10784079 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 158
Study 8678501 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of azasetron (2.5 mg bolus followed by 7.5 mg continuous infusion for 24 hrs)
Number of subjects: 0
Study 8678501 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of azasetron
Number of subjects: 0
Study 8678501 — intervention group
Group type: COMPARATOR
Intervention: Bolus intravenous injection of azasetron (10 mg)
Number of subjects: 0
Study 2059393 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg/day for 8 weeks
Number of subjects: 24